Physician
Hematology
Dr. Alexander K. Stewart, MD
|
|
Give Review
Doctor Alexander K. Stewart, MD practices Hematology. He received 3 awards: "America's Top Doctors", "Top Doctors:Arizona State" and "America's Top Doctors for Cancer". Alexander Stewart is a published doctor and has 34 publications published. The lastest was: 'Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.' Alexander Stewart is registered with Medicare.
Publications
- SnapShot: Multiple Myeloma.
- Longitudinal analysis of 25 sequential sample-pairs using a custom multiple Myeloma mutation sequencing panel (M(3)P).
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed Myeloma.
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple my...
- RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple Myeloma.
- Targeted sequencing using a 47 gene multiple Myeloma mutation panel (M(3) P) in -17p high risk disease.
- Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple Myeloma.
- Identification of cereblon binding proteins and relationship with response and survival following pomalidomide and dexamethasone in multiple Myeloma.
- Multiple Myeloma: genome sequencing, drug development and the future outlook.
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma.
- Medicine. How thalidomide works against cancer.
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
- Mechanism of immunomodulatory drugs' action in the treatment of multiple Myeloma.
- Phase 2 trial of intravenously administered plerixafor for stem Cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- The clinical significance of cereblon expression in multiple Myeloma.
- Genome-wide studies in multiple Myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
- Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple Myeloma.
- Extramedullary Myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.
- Carfilzomib.
- A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem Cell transplantation (ASCT) in patients with multiple myelo...
- Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple Myeloma.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple Myeloma: high response rates in a phase II clinical trial.
- Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antiMyeloma activity in vitro and in vivo.
- High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone Lymphomas.
- Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple Myeloma patients.
- Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem Cell transpla...
- Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements.
- Lessons from next-generation sequencing analysis in hematological malignancies.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- American Enterprise Group
- American Republic
- Assurant Health
- Great West Healthcare-Cigna PPO
- Coventry Health Care
- Delta Health System
- Golden Rule
- GEHA
- HealthSmart
- Humana
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- POMCO Group
- Simplifi
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:Arizona State
- America's Top Doctors for Cancer
Education
-
University of Aberdeen Faculty of Medicine
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER | 1346223013 | |
| NPPES Provider LastName | STEWART | |
| NPPES Provider FirstName | ALEXANDER | |
| NPPES Provider ZIPCode | 852595404 | |
| NPPES Provider State | AZ | |
| Specialty Description | Hematology | |
| Total Claim Count | 455.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 34.0 | |
| Percent Opioid Claims | 7.47 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346223013 |
| Last Name Of The Provider | STEWART |
| First Name Of The Provider | ALEXANDER |
| View All |
Similar Doctors
|
|
Dr. Adrienne D. Briggs, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pierre Noel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa O. Sproat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Helen J. Ross, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Chad C. Cherington, MD
This Doctor is OpenDoctor Recommended.
|